Provider Briefing: Suprep Bowel Prep Kit Availability in 2026

Suprep Bowel Prep Kit (sodium sulfate/potassium sulfate/magnesium sulfate oral solution) remains one of the most widely prescribed colonoscopy preparation agents in the United States. As a prescriber, you may be fielding increasing calls from patients who can't fill their Suprep prescriptions at their local pharmacy. This briefing covers the current availability landscape, prescribing considerations, cost implications, and practical tools to keep your patients' screening timelines on track.

Current Status: Is There a Formal Shortage?

As of March 2026, Suprep Bowel Prep Kit is not listed on the FDA Drug Shortage Database. Braintree Laboratories (a subsidiary of Sebela Pharmaceuticals) continues to manufacture and distribute the product.

However, the absence of a formal FDA-listed shortage does not reflect the day-to-day experience of many patients attempting to fill prescriptions. Localized pharmacy stock-outs remain common across the country. The practical availability gap is driven by several converging factors outlined below.

Timeline and Context

Understanding the broader context helps explain current availability patterns:

• 2010: Suprep Bowel Prep Kit receives FDA approval (NDA 022372)
• 2018-2021: Significant growth in prescribing volume as gastroenterologists increasingly favor sulfate-based, low-volume preps over traditional 4-liter PEG solutions
• 2021: US Preventive Services Task Force lowers recommended screening age from 50 to 45, expanding the eligible screening population by approximately 20 million adults
• 2023-2025: FDA approves generic versions of Suprep (sodium sulfate/potassium sulfate/magnesium sulfate oral solution), triggering a market transition period
• 2026: Both brand and generic remain available, but pharmacy-level stock-outs persist due to demand and stocking practices

Prescribing Implications

Generic Substitution

FDA-approved generic versions of Suprep are now available from multiple manufacturers. Unless you write "dispense as written" (DAW), pharmacies will typically substitute the generic automatically. The generic contains the same active ingredients at the same concentrations and is therapeutically equivalent.

For patients reporting that Suprep is "unavailable," the first step is confirming whether the pharmacy carries the generic. In many cases, the generic is in stock even when brand-name Suprep is not.

Prescribing Flexibility

Consider building flexibility into your prescribing workflow:

• Prescribe by generic name (sodium sulfate/potassium sulfate/magnesium sulfate oral solution) to allow pharmacies maximum dispensing flexibility
• Include a note on the prescription allowing therapeutic substitution if Suprep-class preps are unavailable
• Pre-identify 1-2 alternative preps for your practice, so staff can quickly pivot when patients call about availability issues

Special Populations

Suprep's contraindications and precautions remain unchanged in 2026. Exercise particular caution with:

• Patients with chronic kidney disease (risk of electrolyte disturbance and renal impairment)
• Patients on medications that affect electrolyte balance (diuretics, ACE inhibitors, ARBs, NSAIDs)
• Patients with heart failure or prolonged QT syndrome
• Patients with history of seizures
• Elderly patients with comorbidities

For these populations, a PEG-based prep like GoLYTELY or Plenvu may be preferred, as PEG preps generally carry a lower risk of electrolyte disturbance.

Availability Picture

The current availability landscape for bowel prep agents:

• Suprep (brand): Intermittently available — pharmacy stocking varies significantly by region and chain
• Suprep generic: Increasingly available as more manufacturers enter the market. Often in stock where brand-name is not.
• GoLYTELY (PEG generic): Widely available at virtually all pharmacies. Most reliable backup option.
• Sutab: Broadly available. Only tablet-based option. Good alternative for patients with liquid intolerance.
• Clenpiq: Available at most pharmacies. Ultra-low volume may improve compliance for reluctant patients.
• Plenvu: Available but brand-only (no generic). Higher cost may be a barrier.

Cost and Access Considerations

Cost is a significant factor in prep selection, particularly for uninsured patients or those with high-deductible plans:

• Suprep (brand): $124-$170 cash price
• Suprep (generic): $35-$75 with discount cards (GoodRx, SingleCare)
• GoLYTELY (generic): $10-$30 — most affordable option
• Sutab: $75-$150
• Clenpiq: $150-$250
• Plenvu: $150-$200

Most commercial insurance plans and Medicare Part D cover bowel prep medications, though formulary placement and copay tiers vary. The Braintree Laboratories savings voucher (available at suprepkit.com) offers up to $15 off the copay for brand-name Suprep.

For patients facing cost barriers, direct them to our guide on saving money on Suprep Bowel Prep Kit, or consider prescribing generic GoLYTELY as the most cost-effective alternative.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing platform that helps practices locate medications in stock at nearby pharmacies. Consider recommending Medfinder to your patients, or use it within your practice when fielding calls about medication availability.

Streamlining Your Workflow

Practical steps to reduce the administrative burden of prep-related calls:

1. Prescribe early: Send the bowel prep prescription to the pharmacy as soon as the colonoscopy is scheduled — not 3 days before the procedure
2. Use generic naming: Prescribing by generic name increases the chance of successful first-fill
3. Create a prep alternatives protocol: Train front-desk and nursing staff on your preferred alternatives so they can handle patient calls without requiring a physician callback
4. Stock patient information sheets: Provide printed or digital guides on multiple prep options at the scheduling visit
5. Leverage pharmacy partnerships: Build relationships with 1-2 reliable pharmacies (especially independents) that consistently stock bowel prep kits

Looking Ahead

Several trends are likely to shape bowel prep availability going forward:

• Generic expansion: As more generic Suprep manufacturers enter the market, overall supply should stabilize and prices should continue to decline
• Continued screening growth: The age-45 screening guideline will continue to drive increasing demand for all bowel prep agents
• Pipeline products: New formulations and delivery methods for bowel prep are in development, which may introduce additional competition and improve patient options
• Insurance coverage improvements: There is growing regulatory attention to ensuring that colonoscopy prep medications are fully covered under preventive care mandates

Final Thoughts

While Suprep Bowel Prep Kit isn't in a formal FDA-listed shortage, the practical availability challenges are real and affect your patients' ability to complete timely colorectal cancer screening. By prescribing early, using generic names, maintaining a flexible alternatives protocol, and pointing patients to tools like Medfinder, you can minimize procedure cancellations and keep screening rates on track.

For a companion guide focused on helping patients locate medications, see our article on how to help your patients find Suprep Bowel Prep Kit in stock.